| Popis: |
The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive lung adenocarcinoma patients and more recently for first-line treatment of EGFR-mutant T790M negative lung adenocarcinoma, Similarly to previous generation TKIs, despite the high response rate, disease progression eventually occurs and current clinical research is focused on novel strategies to delay the emergence of osimertinib resistance.In this study,we investigated as the combination of osimertinib/ gefitinib/ erlotinib with cytotoxicchemotherapy for EGFR-mutated positivelung adenocarcinoma patientsin long-term survivaloutcomes. |
